Navigation Links
The Treatment Landscape for Hepatocellular Carcinoma Will Change Dramatically Over the Next Ten Years Due to the Launch of New Therapies in the United States and EU5
Date:1/29/2013

BURLINGTON, Mass., Jan. 29, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the treatment landscape for hepatocellular carcinoma in the United States and Europe will change dramatically through 2021 as three new, potentially high priced therapies–Novartis's Afinitor, ArQule's tivantinib and Celsion's ThermoDox–arrive on the market, thereby greatly increasing treatment options in patient populations in which there is no approved standard-of-care drug therapy.

According to Niche Markets and Rare Diseases: Hepatocellular Carcinoma, of the forecasted emerging therapies, Afinitor will be the first drug to gain regulatory approval and will launch in 2014 in all markets under study for treatment of advanced hepatocellular carcinoma in the second-line setting following disease progression on Bayer HealthCare/Onyx Pharmaceuticals' Nexavar, the current patient-share leader. By 2021, tivantinib will also launch in the second-line setting for treatment of patients who express high levels of c-MET. ThermoDox, a heat-sensitive liposome-encapsulated formulation of doxorubicin, will be the only therapy to launch over the next ten years in the localized/locally advanced setting for use in combination with radiofrequency embolization (RFA).

"According to opinion leaders, one of the greatest unmet needs in the hepatocellular carcinoma space is for a second-line therapy directed at patients who cannot tolerate treatment with or progress on Nexavar–the standard-of-care in the first-line setting through 2021," said Decision Resources Analyst Karen Pomeranz , Ph.D. "However, the launch of ThermoDox will herald a novel treatment approach in loc
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 ... Summary GlobalData,s new ... provides key market data on the Brazil Gynecological ... of US dollars, volume (in units) and average ... Female Sterilization Devices (Transcervical Sterilization Devices (Micro-inserts) and ...
(Date:9/17/2014)... Sept. 17, 2014  Levi & Korsinsky, LLP is ... possible claims of breaches of fiduciary duty by the ... get more information, click here: http://zlk.9nl.com/alexza-pharmaceuticals-alxa . There ... If you own common stock in Alexza Pharmaceuticals Inc. ... Eduard Korsinsky, Esq. either via email at ...
(Date:9/17/2014)... PITTSBURGH , Sept. 17, 2014 /PRNewswire-iReach/ ... a white paper discussing improvements in the ... anatomic structures for both normal and diseased ... real-time information, simplifies surgical procedures, lowers surgical ... robot-assisted surgical procedures. The ...
Breaking Medicine Technology:Brazil Gynecological Devices Market Outlook to 2020 2Brazil Gynecological Devices Market Outlook to 2020 3Patient Outcomes Improve When Molecular Chemical Imaging Technology Is Used to Aid Robotic Surgical Procedures, According to New White Paper 2
... ... Schizophrenia, WASHINGTON, MAY 6 Data ... candidate,iloperidone, included its 4-week, short-term Phase III trial, as well as ... of iloperidone. Iloperidone is a 5HT2/D2 antagonist ("atypical"),antipsychotic currently under review ...
... - Data Presented in Poster Session at American College ... Gynecologists, 56th Annual ... PEAK Surgical, Inc., a medical,device company that is ... released results from a preclinical study,demonstrating that its PEAK ...
Cached Medicine Technology:Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events 2Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events 3Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events 4Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events 5Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events 6Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events 7PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery 2PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery 3PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery 4
(Date:9/18/2014)... 2014 N-Zyme Scientifics LLC achieved a ... first product a mere 8 months after company startup. ... performance glycan release enzyme used in the “Biologics” industry ... basis for tissue pathology on Mass Spec devices. PRIME™ ... the North American market (PNGase F PRIMETM). N-Zyme ...
(Date:9/18/2014)... 2014 9Lover.com, an internationally well-known designer ... launched a big promotion for its maternity wedding outfits. ... buy discounted maternity wedding dresses on its ... to all global consumers. The company’s development manager believes ... of ladies delighted. The current special offer will last ...
(Date:9/17/2014)... Fecbek, a leading dress manufacturer and retailer, has delightedly announced ... a lot of beautiful A-line dresses, maxi dresses, mini dresses ... skirt is a tube- or cone-shaped garment that hangs from ... In the western world, skirts are considered women's clothing. At ... is made out of a single piece of material (such ...
(Date:9/17/2014)... Recently, UWDress.com, an innovative company that provides many ... has released its 2014 empire waist evening dress ... a big sale for these new and beautiful products. ... rates, from 15 to 65 percent off. , ... comfortable to wear materials. Its elegant items include gold ...
(Date:9/17/2014)... (PRWEB) September 18, 2014 IntimateRider, an ... disabled adults , has announced that it has entered ... Medical & Mobility LLC. A primary reason for the ... Mobility's distribution reach is global. About its sales potential, ... strive to provide you with the latest products on ...
Breaking Medicine News(10 mins):Health News:N-Zyme Scientifics Announces Successful Product Launch 2Health News:Discounted Maternity Wedding Dresses For 2014 Introduced By 9Lover.com 2Health News:Fecbek.com Has Recently Announced Its New Series of Delicate Special Occasion Gowns Online 2Health News:2014 Empire Waist Evening Dress Collection Now Unveiled At UWDress.com 2Health News:IntimateRider Announces All Terrain Medical & Mobility as Its New Dealer 2Health News:IntimateRider Announces All Terrain Medical & Mobility as Its New Dealer 3
... one in 70 schoolchildren, available data says. The question is ... joint team of scientists from the King's College London ... up a seven-year study and hope to rope in 480 ... studied are between four and 11 months and already have ...
... news for the Bush administration in the US. A ... and Afghanistan is posing a serious challenge on two fronts. ... of mental health problems. Second at the current level of ... able to provide those affected necessary statement. ,In ...
... a campaign to encourage Hispanics to eat healthier food, ... Hispanics increased from 11.6% in 1991 to 23.7% in ... and two times more likely to have diabetes than ... ,LNC's campaign features a "Latin American Diet ...
... in the reduction of Alzheimer’s symptoms in mice. This promises ... a deadly brain disorder, scientists hope. ,Dr. Lennart ... this strategy also works in humans, it could enable a ... whose work is published in the journal Science, studied mice ...
... spectacle when she had epileptic seizures, almost 30 a day. What ... had a scowl and a guttural sinister laughter would emanate from ... to be named as "The Joker face," by her physician, Dr. ... ,This girl, all of 3 years suffered a very uncommon ...
... and practice is needed to achieve dignified care for older ... ,The welfare of older people who live in care homes ... McMurdo and Miles Witham at the University of Dundee. ... to dignity, but people of all ages have a fundamental ...
Cached Medicine News:Health News:UK Scientists to Undertake Seven Year Study of Peanut Allergy 2Health News:One Third of US Troops Suffer from Mental Health Problems 2Health News:One Third of US Troops Suffer from Mental Health Problems 3Health News:Major Change Needed to Achieve Dignified Care for Older People 2
Heavy duty, all purpose illuminator available in black only. Unique Clip Switch automatically turns off when returned to pocket. Pre-focused lens tip Heine XHL Halogen bulb for bright, concentrated l...
Convenient clip-activated switch with removable cobalt blue filter attachment....
Convenient clip-activated switch with imprinted 2 mm - 9 mm pupil gauge and medical caduceus....
... most affordable, compact and lightweight video magnifier. ... 18 pounds, the Companion is the perfect ... Companions easy-to-use controls allow you to read ... magazines, newspapers and even curved surfaces on ...
Medicine Products: